For (ex)entrepreneurs, families, wealthy individuals, business professionals, healthcare professionals and executives.
For family offices, foundations & charities and independent asset managers.
For institutional and wholesale clients.
For corporates, institutional investors and private equity.
Van Lanschot Kempen closely monitors markets and economic developments. Stay informed and up to date on current topics. Read our articles, watch our videos and listen to our podcasts.
Read more about our organisation, news, investor relations and our contribution to a sustainable society.
Read more about working at Van Lanschot Kempen and view current vacancies.
Read more about Evi, our online investment coach.
Read more about our expertise and offices in different countries.
Are you already a client or interested in our services? We are happy to help you.
We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
0800 17 37Belgium
+32 (0)32 86 69 80Switzerland
+41 (0)43 377 11 11We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 87 00United Kingdom
+44 (0)20 36 36 94 00France
+33 (0)18 375 62 73We are happy to speak to you in person. Call us or click on the link below for more contact options and locations.
The Netherlands
+31 (0)20 348 80 00United Kingdom
+44 (0)20 36 36 94 00United States of America
+1 (0)21 237 601 34Joint Global Coordinator and Joint Bookrunner
Kempen & Co is pleased to announce that it acted as Joint Global Coordinator and Joint Bookrunner in Xbrane’s SEK 380m Capital Increase
Xbrane is a biopharmaceutical company that develops biosimilars based on a proprietary platform. Xbrane’s lead product - Xlucane - a biosimilar candidate to Lucentis®, addresses ophthalmic VEGFa inhibitor market. Marketing authorization and launch of Xlucane is expected for H2 2022. Xlucane is partnered with biosimilar specialist STADA and ophthalmology specialist Bausch+Lomb for commercialization. Xbrane's pre-clinical candidates include Xcimzane - biosimilar to Cimzia currently under development, and Xdivane - a biosimilar to Opdivo. Xbrane's ambition is to initiate one new biosimilar development program annually and become cash-flow positive by late 2023/early 2024
In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include: